Table 1 Association of HMGI-C expression with clinicopathologic characteristics of patients
HMGI-C expression | |||
|---|---|---|---|
Variables | Positive (%) | Negative (%) | P -value a |
Age (years) | |||
Mean±s.d. | 55.6±7.8 | 56.0±13.1 | 0.80 |
Range | 39.9−71.9 | 32.1−85.1 | |
Median | 55.3 | 58.4 | |
Time from diagnosis to first metastatic event (months) | |||
Mean±s.d. | 27.1±19.8 | 31.0±31.0 | 0.87 |
Range | 0.0−85.0 | 0.0−120.0 | |
Median | 23.0 | 25.5 | |
Menopausal status | 0.18 | ||
Premenopausal | 0 (0) | 5 (10.4) | |
Postmenopausal | 19 (90.5) | 38 (79.2) | |
Unknown | 2 (9.5) | 5 (10.4) | |
Histology | 1.00 | ||
Ductal carcinoma | 20 (95.2) | 45 (93.8) | |
Lobular carcinoma | 1 (4.8) | 3 (6.2) | |
Oestrogen-receptor status | 0.78 | ||
Positive | 11 (52.4) | 27 (56.2) | |
Negative | 8 (38.1) | 16 (33.3) | |
Unknown | 2 (9.5) | 5 (10.4) | |
Progesterone-receptor status | 0.79 | ||
Positive | 8 (38.1) | 19 (39.6) | |
Negative | 12 (57.1) | 24 (50.0) | |
Unknown | 1 (4.8) | 5 (10.6) | |
Site of metastases | |||
Any visceral | 19 (90.5) | 39 (81.3) | 0.48 |
Lung | 12 (57.1) | 25 (52.1) | 0.80 |
Liver | 12 (57.1) | 20 (41.7) | 0.29 |
Lung and Liver | 5 (23.8) | 8 (16.7) | 0.52 |
Bone | 14 (66.7) | 21 (42.6) | 0.12 |
Soft tissues | 5 (23.8) | 13 (27.1) | 1.00 |
Chemotherapy | |||
Ever | 16 (76.2) | 29 (60.4) | 0.28 |
Adjuvant | 12 (57.1) | 20 (41.7) | 0.30 |
Previous palliative | 7 (33.3) | 10 (20.8) | 0.36 |
Anthracyclines | 9 (42.9) | 19 (39.6) | 1.00 |
Taxanes | 7 (33.3) | 10 (20.8) | 0.37 |
Endocrine therapy | 12 (57.1) | 29 (60.4) | 1.00 |
Tamoxifen | 11 (52.4) | 26 (54.2) | 1.00 |
Letrozole | 3 (14.3) | 13 (27.1) | 0.36 |
Radiation therapy | 12 (57.1) | 22 (45.8) | 0.44 |
